Compare DK & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DK | VKTX |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.0B |
| IPO Year | 2017 | 2014 |
| Metric | DK | VKTX |
|---|---|---|
| Price | $74.25 | $28.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 20 |
| Target Price | $76.77 | ★ $94.71 |
| AVG Volume (30 Days) | 2.0M | ★ 7.6M |
| Earning Date | 11-06-2026 | 10-21-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 95.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.50 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.85 | $25.77 |
| 52 Week High | $82.27 | $43.15 |
| Indicator | DK | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 40.20 |
| Support Level | $61.60 | N/A |
| Resistance Level | $77.40 | $35.23 |
| Average True Range (ATR) | 3.37 | 2.25 |
| MACD | 0.12 | -0.58 |
| Stochastic Oscillator | 74.61 | 8.97 |
Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has three segments: Refining segment and Logistics segment and retail segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.